Compare Stocks Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. OTCMKTS:IGXTNYSEMKT:PHGENASDAQ:PHXMNASDAQ:TVGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47102,577 shsN/APHGEBiomX$1.02-2.9%$0.55$0.00▼$0.00$71.20M1.368,601 shs41,217 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ATVGNTevogen Bio$0.46+4.5%$0.58$0.40▼$21.09$76.41M0.36488,400 shs372,213 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXTIntelGenx Technologies0.00%0.00%0.00%0.00%+18.02%PHGEBiomX+2.88%+2.88%+622.97%+222.29%+197.22%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%-38.86%TVGNTevogen Bio+1.71%-11.11%-28.71%-44.99%+43,999,900.00%Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.”MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGXTIntelGenx Technologies0.2395 of 5 stars0.24 / 5 stars0.03.00.00.00.61.70.0PHGEBiomX1.4651 of 5 stars1.47 / 5 stars3.50.00.00.00.00.80.6PHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATVGNTevogen Bio3.5723 of 5 stars3.57 / 5 stars3.55.00.00.00.01.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGXTIntelGenx TechnologiesN/AN/AN/AN/APHGEBiomX3.00Buy$2.25120.59% UpsidePHXMPHAXIAM TherapeuticsN/AN/AN/AN/ATVGNTevogen Bio3.00Buy$4.20813.04% UpsideCurrent Analyst RatingsLatest PHGE, TVGN, PHXM, and IGXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/16/2024PHGEBiomXHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.00 ➝ $2.006/28/2024TVGNTevogen BioFundamental ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy$4.20(Data available from 9/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39PHGEBiomXN/AN/AN/AN/A$0.70 per shareN/APHXMPHAXIAM Therapeutics$32.66M0.32N/AN/A$7.98 per share0.39TVGNTevogen BioN/AN/AN/AN/A($1.10) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/A-1,049.48%N/A-158.32%N/APHGEBiomX-$28.32M-$0.61N/AN/AN/AN/A-127.82%-56.50%N/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ATVGNTevogen Bio-$70KN/A0.00∞N/AN/A-387.78%434.75%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGXTIntelGenx TechnologiesN/A0.130.12PHGEBiomX0.512.842.84PHXMPHAXIAM Therapeutics0.231.78N/ATVGNTevogen BioN/A0.230.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGXTIntelGenx TechnologiesN/APHGEBiomX40.57%PHXMPHAXIAM Therapeutics0.40%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipIGXTIntelGenx Technologies42.05%PHGEBiomX3.01%PHXMPHAXIAM Therapeutics1.94%TVGNTevogen Bio56.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionablePHGEBiomX12069.81 million44.04 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataTVGNTevogen Bio17166.11 million72.09 millionN/APHGE, TVGN, PHXM, and IGXT HeadlinesRecent News About These CompaniesTevogen Bio Holdings Inc.September 17 at 2:59 PM | wsj.comTevogen Bio Holdings Inc (TVGN) Stock: Surpassing Expectations in the MarketSeptember 12, 2024 | bovnews.comShort Interest in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Grows By 28.6%August 31, 2024 | marketbeat.comTevogen Bio Secures $6 Million Series C Preferred Stock InvestmentAugust 22, 2024 | markets.businessinsider.comWalmart Shares Jump on Q2 Earnings Beat, Guidance RaiseAugust 15, 2024 | au.finance.yahoo.comGap between Mag 7, rest of market is 'narrowing' in late 2024August 15, 2024 | uk.finance.yahoo.comCORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesAugust 15, 2024 | globenewswire.comTevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s ...August 15, 2024 | bakersfield.comTevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesAugust 15, 2024 | globenewswire.comCheck out this $800 rotating VR chair for Meta QuestAugust 14, 2024 | au.finance.yahoo.comTevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public HealthAugust 14, 2024 | globenewswire.comTevogen Bio Holdings Inc. (G28.F)August 12, 2024 | nz.finance.yahoo.comTevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and ...August 9, 2024 | bakersfield.comTevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive SecuritiesAugust 9, 2024 | globenewswire.comTevogen Bio Holdings Inc (TVGN)July 28, 2024 | uk.investing.comTevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share BuybackJuly 11, 2024 | globenewswire.comTevogen Bio's R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina AyanianJuly 10, 2024 | globenewswire.comRyan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social ResponsibilityJuly 8, 2024 | globenewswire.comTevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive SecuritiesJune 26, 2024 | globenewswire.comTevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood AdvancesJune 25, 2024 | globenewswire.comTevogen.AI Head Discusses Company's Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT ConferenceJune 18, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIntelGenx TechnologiesOTCMKTS:IGXTIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.BiomXNYSEMKT:PHGEBiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.PHAXIAM TherapeuticsNASDAQ:PHXMPHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Tevogen BioNASDAQ:TVGNTevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.